Journal: Malaria Journal

Article Title: In vitro activity and in vivo efficacy of omadacycline against Plasmodium species

doi: 10.1186/s12936-025-05448-w

Figure Lengend Snippet: Suppression of P. berghei parasite luminescence signal by omadacycline in A liver (48 h) and B early blood stage (72 h) in a murine causal prophylaxis assay. Each timepoint represents the mean ± SEM bioluminescence signal emitted by A liver and B whole body area for n = 5 mice (all treatment groups, except for the Tafenoquine treated group (n = 4)). OMC = omadacycline; Doxy = doxycycline; VC = vehicle control; IP = intraperitoneal; PO = oral; QD = once daily. Note: The value emitted by clear skin [1.59E+05 photons/sec (LOG = 5.2)] was used for animals in which no bioluminescence signal was detected in the body area

Article Snippet: For in vivo efficacy studies, drugs tested were obtained from the following vendors: Omadacycline, 100 mg/vial for injection (Paratek Pharmaceuticals, Inc., King of Prussia, PA); Tafenoquine and 4-Methyl primaquine (WR238605-21 and WR181023-7, respectively; WRAIR, Experimental Therapeutics Branch Repository, Specs US Compound Management Facility, Cumberland, MD); Doxycycline hyclate catalog #D989 (Sigma Aldrich, St. Louis, MO).

Techniques: Control

Journal: Malaria Journal

Article Title: In vitro activity and in vivo efficacy of omadacycline against Plasmodium species

doi: 10.1186/s12936-025-05448-w

Figure Lengend Snippet: Omadacycline increased animal survival during blood stage P. berghei malaria infection in a dose-dependent manner. The effects of omadacycline on mouse survival after P. berghei infection were determined via the Kaplan–Meier method. All treatment groups were significantly more effective than VC (p < 0.05). *OMC30 and OMC20 mg/kg (but not OMC10 and OMC5) significantly extended animal survival time compared to Doxycycline 120 mg/kg (p < 0.05). TQ was significantly more effective than all other treatment groups (p < 0.05). OMC = omadacycline (OMC30 mg/kg = dark blue squares and dots, OMC20 mg/kg = turquoise lines and black triangles; OMC10 mg/kg = light blue line and black triangles, OMC5 mg/kg = light blue lines and black diamonds); Doxy = doxycycline (dark olive triangles); tafenoquine (dark red circle); primaquine (bright orange squares); VC = vehicle control (dark green circles); IP = intraperitoneal; PO = oral

Article Snippet: For in vivo efficacy studies, drugs tested were obtained from the following vendors: Omadacycline, 100 mg/vial for injection (Paratek Pharmaceuticals, Inc., King of Prussia, PA); Tafenoquine and 4-Methyl primaquine (WR238605-21 and WR181023-7, respectively; WRAIR, Experimental Therapeutics Branch Repository, Specs US Compound Management Facility, Cumberland, MD); Doxycycline hyclate catalog #D989 (Sigma Aldrich, St. Louis, MO).

Techniques: Infection, Control

Journal: Malaria Journal

Article Title: In vitro activity and in vivo efficacy of omadacycline against Plasmodium species

doi: 10.1186/s12936-025-05448-w

Figure Lengend Snippet: IC 50 curves for doxycycline and omadacycline in vitro anti- Plasmodium activity. Plots display log micromolar concentration vs percent inhibition, with black dashed dotted line as 0%, and error bars representing standard error mean of single assay replicates. A , B P. falciparum blood stage SYBR Green assay. C , D Liver stage P. cynomolgi assay

Article Snippet: For in vivo efficacy studies, drugs tested were obtained from the following vendors: Omadacycline, 100 mg/vial for injection (Paratek Pharmaceuticals, Inc., King of Prussia, PA); Tafenoquine and 4-Methyl primaquine (WR238605-21 and WR181023-7, respectively; WRAIR, Experimental Therapeutics Branch Repository, Specs US Compound Management Facility, Cumberland, MD); Doxycycline hyclate catalog #D989 (Sigma Aldrich, St. Louis, MO).

Techniques: In Vitro, Activity Assay, Concentration Assay, Inhibition, SYBR Green Assay